Partnering opportunity

A French Technology Transfer Office offers a novel anti-inflammatory therapeutic


The French TTO (Technology Transfer Office) is acting on behalf of an established public laboratory of the Paris region that has designed and patented a series of peptides acting as anti-inflammatories. The French public research centre is looking for interested pharmacology corporates or biotechnology for a technical cooperation, research agreement or license agreement.

Partner sought

The partner sought could be a pharma or biotech company interested in : - a licencing agreement as the TTO is ready to negotiate directly the patents rights for specific applications. - a technical cooperation. The eventual partner should have a clear industrial application in mind and a strong technical background to co-develop an eventual treatment with the laboratory. - a research cooperation agreement if the partner is ready to co-develop new models of the peptides or to complete the pre-clinical data (4 animal models can be tested for Multiple sclerosis). A research agreement between the laboratory and a compagny can be partielly funded by the TTO.


A French Technology Transfer Office (TTO) is acting on behalf several major engineering and medical schools in the Paris region. A research team operating in biochemical has designed a series of peptides acting as anti-inflammatories. * Market challenges : Inflammation is a critical response to potential danger signals in organs in our body. In diseases such as multiple sclerosis, rheumatoid arthritis, lupus, ulcerative colitis, Crohn's disease and others, the immune system turns against the bodies' organs. These painful and, in some cases, progressively degrading conditions can take a toll on people's quality of life and create both societal and economic burdens. * State of the art : Although there are multiple anti-inflammatory drugs approved in the market, there is an indispensable need for better and novel anti-inflammatory therapeutics with lesser side effects and better efficacy. * Proposed technology : CCR2 (C-C chemokine receptor type 2) is a chemokine receptor member of the G-protein coupled receptor family. The G-protein is a protein that allows the transfer of information inside the cell. It is expressed by monocytes and memory T lymphocytes. CCL2 (Chemokine ligand 2) is a potent chemotactic factor which, after binding to CCR2, mediates monocyte and lymphocyte migration toward a site of inflammation. Animal model studies of chronic inflammatory diseases have demonstrated that inhibition of binding between CCL2 and CCR2 by an antagonist suppresses the inflammatory response. The French researchers have designed a series of small peptidesacting like CCR2 antagonists. These peptides act by destabilizing the interaction between the CCR2 receptor and their natural ligands, preventing the activation of the pro-inflammatory cascade. They constitute potential anti-inflammatory agents by blocking the infiltration of monocytes in affected tissues. This technology has several potential applications for preventive strategies or treatment of inflammatory disorders and helps to muscle regeneration. *Partnership : The partner sought could be a company interested in : - a license agreement as the TTO is ready to negociate directly the patents rights for specific applications, or - a technical cooperation agreement if the industrial application can benefit directly from the actual models -a research coopération if the industrial is ready to to co-develop new models of the peptides or to complete the pre-clinical data. *Keywords : #CCR2 receptor #inflammatory diseases #non-competitive inhibition #peptide

Advantages and innovations

This series of peptide has got the following advantages : · Selectivity and specificity · Non competitive antagonist · Small size (7 amino acid peptides) so it does not trigger an immune response · Easy to synthesize · Good resistance to biodegradation · Fewer side effects The peptides were chemically marked (Fluorescence) to appear easily in imaging. This marking makes it possible to observe the biodistributuion of these peptides in the tissues which makes the future tests easier. This technique also makes it possible to clearly visualize the inflammatory zones.

Development stage

Under development/lab tested

Intellectual Property Rights (IPR)

Patents granted

Register your interest

How it works

  • Tell us about yourself
  • We’ll discuss with you
  • We put the right partners in touch

EEN help you find the right partner, rather than you going it alone.

Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.

These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.

Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.

?What value does EEN add?
This is your pitch: remember to include your unique selling points (USP) and why someone would want to do business with you
Tell us why you are a good fit for this opportunity, and why you think you're the right people for this partnership
If there's anything additional, or commercially sensitive you'd like to know about this opportunity, please let us know

When you entered your email address above, we emailed you a code to verify you're human and have access to that account.

?What's this?

What next?

To finish up, we just need some extra details about you and your company